NCT02034474View on ClinicalTrials.gov

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Tocilizumab

8mg/kg intravenously via iv drip over 60 min

DRUG

Placebo

intravenously via iv drip over 60 min

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT02034474 - Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter